Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ivan Krecak, Marko Skelin & Srdan Verstovsek. (2023) Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera. Expert Review of Hematology 16:5, pages 305-316.
Read now
Read now
Eran Zimran, Alla Keyzner, Camelia Iancu-Rubin, Ronald Hoffman & Marina Kremyanskaya. (2018) Novel treatments to tackle myelofibrosis. Expert Review of Hematology 11:11, pages 889-902.
Read now
Read now
Articles from other publishers (22)
Hans Carl Hasselbalch, Vibe Skov, Lasse Kjær & Morten Kranker Larsen. (2023)
Proof of concept of triple
COMBI
therapy to prohibit
MPN
progression to
AML
. British Journal of Haematology.
Crossref
Crossref
Hans Carl Hasselbalch, Peter Junker, Vibe Skov, Lasse Kjær, Trine A. Knudsen, Morten Kranker Larsen, Morten Orebo Holmström, Mads Hald Andersen, Christina Jensen, Morten A. Karsdal & Nicholas Willumsen. (2023) Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms. Cancers 15:17, pages 4323.
Crossref
Crossref
Eli M. Soyfer & Angela G. Fleischman. (2023) Myeloproliferative neoplasms – blurring the lines between cancer and chronic inflammatory disorder. Frontiers in Oncology 13.
Crossref
Crossref
Sylvie Hermouet. (2023) Mutations, inflammation and phenotype of myeloproliferative neoplasms. Frontiers in Oncology 13.
Crossref
Crossref
Marc J. B. Dam, Rasmus K. Pedersen, Trine A. Knudsen, Morten Andersen, Christina Ellervik, Morten Kranker Larsen, Lasse Kjær, Vibe Skov, Hans C. Hasselbalch & Johnny T. Ottesen. (2022)
A novel integrated biomarker index for the assessment of hematological responses in
MPNs
during treatment with hydroxyurea and interferon‐alpha2
. Cancer Medicine 12:4, pages 4218-4226.
Crossref
Crossref
Hans Hasselbalch, Vibe Skov, Lasse Kjær, Morten Kranker Larsen, Trine A. Knudsen, Marko Lucijanić & Rajko Kusec. (2022) Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives. Cancers 14:22, pages 5495.
Crossref
Crossref
Miklos Egyed, Bela Kajtar, Csaba Foldesi, Vibe Skov, Lasse Kjær & Hans Carl Hasselbalch. (2022) Ropeginterferon-alfa2b resolves angina pectoris and reduces JAK2V617F in a patient with clonal hematopoiesis of indeterminate potential: A case report. Frontiers in Hematology 1.
Crossref
Crossref
Vibe Skov, Mads Thomassen, Lasse Kjær, Christina Ellervik, Morten Kranker Larsen, Trine Alma Knudsen, Torben A. Kruse & Hans C. Hasselbalch. (2022) Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms. PLOS ONE 17:6, pages e0270669.
Crossref
Crossref
Hans C. Hasselbalch & Richard T. Silver. (2021) New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms. HemaSphere 5:12, pages e645.
Crossref
Crossref
Hans Carl Hasselbalch, Margitta Elvers & Andrew I. Schafer. (2021) The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. Blood 137:16, pages 2152-2160.
Crossref
Crossref
Sophie Allain-Maillet, Adrien Bosseboeuf, Nicolas Mennesson, Mégane Bostoën, Laura Dufeu, Eun Ho Choi, Cédric Cleyrat, Olivier Mansier, Eric Lippert, Yannick Le Bris, Jean-Marc Gombert, François Girodon, Magali Pettazzoni, Edith Bigot-Corbel & Sylvie Hermouet. (2020) Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms. Cancers 12:9, pages 2446.
Crossref
Crossref
Vibe Skov. (2020) Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. Cancers 12:8, pages 2194.
Crossref
Crossref
Joan How & Gabriela Hobbs. (2020) Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature. Cancers 12:7, pages 1954.
Crossref
Crossref
Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, Mads Emil Bjørn, Christen Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Dustin Andersen Patel, Lise Mette Rahbek Gjerdrum, Daniel El Fassi, Torben A. Kruse, Thomas Stauffer Larsen, Hans Torben Mourits-Andersen, Claus Henrik Nielsen, Christina Ellervik, Niels Pallisgaard, Mads Thomassen, Lasse Kjær, Vibe Skov & Hans Carl Hasselbalch. (2020) Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica 105:9, pages 2262-2272.
Crossref
Crossref
Rasmus K. Pedersen, Morten Andersen, Trine A. Knudsen, Zamra Sajid, Johanne Gudmand‐Hoeyer, Marc J. B. Dam, Vibe Skov, Lasse Kjær, Christina Ellervik, Thomas S. Larsen, Dennis Hansen, Niels Pallisgaard, Hans C. Hasselbalch & Johnny T. Ottesen. (2020)
Data‐driven analysis of
JAK2
V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
. Cancer Medicine 9:6, pages 2039-2051.
Crossref
Crossref
Yingying Wang & Xuelan Zuo. (2019) Cytokines frequently implicated in myeloproliferative neoplasms. Cytokine: X 1:1, pages 100005.
Crossref
Crossref
Hans Carl Hasselbalch & Morten Orebo Holmström. (2018) Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?. Seminars in Immunopathology 41:1, pages 5-19.
Crossref
Crossref
Stine Ulrik Mikkelsen, Lasse Kjaer, Mads Emil Bjørn, Trine Alma Knudsen, Anders Lindholm Sørensen, Christen Bertel Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Daniel El Fassi, Torben A. Kruse, Thomas Stauffer Larsen, Hans Torben Mourits-Andersen, Claus Henrik Nielsen, Niels Pallisgaard, Mads Thomassen, Vibe Skov & Hans Carl Hasselbalch. (2018) Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Medicine 7:8, pages 3571-3581.
Crossref
Crossref
Rasmus Tolstrup Larsen, Lars H. Tang, Nana Brochmann, Esben Meulengracht Flachs, Anne Illemann Christensen, Hans C. Hasselbalch & Ann‐Dorthe Zwisler. (2018) Associations between fatigue, physical activity, and QoL in patients with myeloproliferative neoplasms. European Journal of Haematology 100:6, pages 550-559.
Crossref
Crossref
Brianna Craver, Kenza El Alaoui, Robyn Scherber & Angela Fleischman. (2018) The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies. Cancers 10:4, pages 104.
Crossref
Crossref
Zen KOBAYASHI, Yoshiyuki NUMASAWA & Shuzo SHINTANI. (2018) Clinical Features and Treatment of Patients With Essential Thrombocythemia本態性血小板血症の臨床像と治療. JOURNAL OF THE JAPANESE ASSOCIATION OF RURAL MEDICINE 67:1, pages 1-8.
Crossref
Crossref
William Vainchenker, Emilie Leroy, Laure Gilles, Caroline Marty, Isabelle Plo & Stefan N. Constantinescu. (2018) JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Research 7, pages 82.
Crossref
Crossref